Joel Adams & Associates’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
Other funds holding LLY
Joel Adams & Associates's LLY Position: Q3 2026 in Review
Joel Adams & Associates reduced its Eli Lilly (LLY) stake by 1% in Q3 2026, selling an estimated $26K and leaving 2,111 shares worth $2.44M. The position accounts for 1.55% of the portfolio, ranked #13.
Joel Adams & Associates first reported a position in LLY in Q4 2024 and has held it in 8 quarters since. The position peaked at $2.56M in Q2 2026. 4,631 funds tracked by Wall St. Rank hold LLY as of Q3 2026.
- Joel Adams & Associates held 2,111 shares of Eli Lilly worth $2.44M as of Q3 2026.
- Joel Adams & Associates sold 22 Eli Lilly shares in Q3 2026, an estimated $26K.
- Eli Lilly made up 1.55% of Joel Adams & Associates's portfolio in Q3 2026, its #13 holding.
- Joel Adams & Associates first reported a position in Eli Lilly in Q4 2024 and has held it in 8 quarters since.
- Joel Adams & Associates's Eli Lilly position peaked at $2.56M in Q2 2026.
- 4,631 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.
Based on Joel Adams & Associates's 13F filing for Q3 2026, filed 2 Nov 2026.